Navigation Links
PointCross Releases Pre-Clinical Study Lifecycle and Data Management Suite (PC-LDM(TM)) For Multi-Party Environments
Date:10/4/2007

PC-LDM ENSURES COMPLIANCE WITH THE SEND FORMAT FOR DATA EXCHANGE AND

ELECTRONIC SUBMISSIONS

FOSTER CITY, Calif., Oct. 4 /PRNewswire/ -- PointCross announced today the release of its PC-LDM(TM) Suite that allows Pharmaceutical and Biotechnology companies to instantly become compliant with SEND (Standard for Exchange of Non-Clinical Data), a CDISC (Clinical Data Interchange Standards Consortium) standard. FDA is anticipating that SEND will replace its current paper or PDF submission formats as indicated in the Federal Register Notice for a Regulatory SEND Pilot (http://www.fda.gov/OHRMS/DOCKETS/98fr/E7-19468.pdf).

Besides SEND compliance, PC-LDM enables global companies to plan the pipeline of studies, exercise control over the conduct of studies, improve study quality, and gain visibility into study progress internally or at a CRO in a highly secure manner. It provides a single, secure environment to orchestrate multi-party workflows, and stakeholder interactions within an individual company, or across the extended enterprise including CROs.

PC-LDM is available either as a SaaS (Software-as-a-Service) model, or deployed within the enterprise.

"The FDA yesterday announced a Regulatory pilot to test the SEND standard and tools for submission and review of nonclinical data including animal toxicology and carcinogenicity data," said Seema Handu, Ph.D., of PointCross. "As the FDA moves towards data-centric electronic submissions, it is essential for sponsor companies to manage their study data throughout the lifecycle of a drug in a standard consistent manner," Dr. Handu added. Dr. Handu has led the SEND Team, a CDISC Working Committee, since its inception in 2002.

"PC-LDM will enable sponsor companies to meet FDA's requirements around SEND as well as other formats that may be required by other agencies," said Shree Nath, Ph.D. "PC-LDM's Semantic Data Exchanger allows data from legacy and on-going studies to be readily available for analysis and data mining, study comparison across similar chemical structures, decision making, and knowledge re-use. This is invaluable considering the amount of information loss due to legacy applications being retired, data currently locked permanently in documents, and inconsistent use of scientific terms by different CROs and individual scientists," added Dr. Nath.

PointCross' PC-LDM offering is built on Orchestra(TM), a scalable, secure SOA platform that provides core capabilities for defining, executing, analyzing and interpreting pre-clinical studies. PC-LDM includes vendor neutral XML-based Operational Data Models (ODMs) for all pre-clinical study types. It allows data exchange across industry standard applications and formats.

About PointCross

PointCross (http://www.pointcross.com) provides advanced strategic business solutions implemented on its Orchestra(TM) platform to knowledge-intensive industries including Pharmaceutical R&D and Upstream Oil and Gas. Besides PC-LDM, PointCross' IDDS (Integrated Drug Development Suite) includes other solutions for specific business processes within the R&D chain such as Lead Optimization, CMC Workbench, and Portfolio/Resource Management. Our customers have realized excellent ROIs and IRRs by using our solutions.


'/>"/>
SOURCE PointCross
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Sweet corn releases antioxidants on cooking
2. An International Growth Standard For Childs Releases By WHO
3. The National Governors Association Releases Guidelines For Outbreak Of Bird Flu
4. Eli Lilly Releases Digital Insulin Pen
5. CDC To Conduct Pre-clinical Trails Of BioDiems Intranasal Bird Flu Vaccine
6. Pre-Clinical Study Suggests How Steroid Can Reverse Post-Traumatic Stress
7. Rural Canadians travel far for specialists: study
8. A new study surpasses Gene Therapy Hurdle
9. Tomato Sauce reduces Cancer Risk- Study
10. A question on study of Adult Stem Cell
11. Study on obesity and heart failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Boca Raton, FL (PRWEB) , ... January 20, 2017 , ... ... combining seaweeds, botanicals and 100 percent pure essential oils, announced the company had a ... Head, SC. , The annual ECRM event gives companies that work in the nutritional, ...
(Date:1/20/2017)... ... , ... Bionic Sports Nutrition LLC, an American company devoted to developing high-quality ... January ECRM Trade Show in Hilton Head, SC. , Bionic Sports Nutrition manufactures ... its products to all clients at reasonable prices. At the ECRM trade show, it ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, an Australian-based company ... attended the January ECRM Trade Show in Hilton Head, SC, benefiting from outstanding ... range of supplements that keep the body functioning at its peak performance by ...
(Date:1/20/2017)... ... ... Michael and Betsy Brauser celebrated 5 years of Betsy’s participation in a ... has been life-saving as she has been on the trial for more than six ... ovarian cancer in 2009. She underwent standard chemotherapy but a year later went to ...
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin Well has launched two ... drinks have been produced in collaboration with Zlatan Ibrahimovic and have been developed ... After a successful launch in Sweden last year, the next generation sports drinks ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , January 19, 2017 Shire ... that the U.S. Food and Drug Administration (FDA) has ... New Drug Application (NDA) for SHP465, a long-acting, triple-bead, ... a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The ... around June 20, 2017, the designated Prescription Drug User ...
(Date:1/19/2017)... CAMBRIDGE, England , January 19, 2017 ... MedImmune and Otsuka in the Milner Therapeutics Consortium   ... academic scientists in Cambridge   ... Inc. (NYSE: PFE ) as a partner ... join the Consortium, which enables the efficient transfer of ...
(Date:1/19/2017)... January 19, 2017 While ... serious about reducing the FDA,s regulatory strictness as ... the medical drug industry, many of the leading ... clinical trials and development of advanced drug treatments ... with recent developments include:  Moleculin Biotech, Inc., (NASDAQ: ...
Breaking Medicine Technology: